Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study (original) (raw)

Abstract

We assessed the activity and tolerability of a cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy in 28 advanced breast cancer patients. The schedule of treatment was as follows: 60 mg/m2 epirubicin followed by 40 mg/m2 cisplatin given on days 1 and 2 every 21 days, with 450 mg lonidamine being given per os (three tablets) on days of chemotherapy administration and in the period intervening between one cycle and the next. Patients received a median of 5 (range 1 – 6) cycles. Overall, 22 patients were evaluable for response and 28, for toxicity. Four patients refused to continue the treatment after the first course, one was lost to follow-up, and one died due to toxicity (septic shock). The incidence of grade 3/4 nausea and vomiting was found to be greater than that expected with epirubicin and lonidamine alone. The addition of cisplatin resulted in an increase in platelet and hemoglobin toxicities, whereas the WBC toxicity did not differ from that expected with epirubicin and lonidamine. The hematological toxicity was found to be cumulative, leading to treatment delay in about 50% of patients at the fifth and sixth courses. The activity of this cytotoxic regimen was noteworthy, with the overall response rate being 81.8% (31.8% complete responses and 50.0% partial responses) in evaluable patients. This response rate decreased to 64.2% when all registered patients were included according to an intent-to-treat analysis. In conclusion, the association of cisplatin, epirubicin, and lonidamine given on the schedule described herein, appears to be very active but substantially toxic. We are now testing this combination in a randomized comparison, with the cisplatin dose being reduced to 30 mg/m2 given on days 1 and 2.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Università di Torino, Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Azienda Ospedaliera San Luigi, Orbassano, Italy, , , , , , IT
    L. Dogliotti, A. Berruti & T. Buniva
  2. Clinica Ostetrica e Ginecologica, Azienda Ospedaliera Sant’Anna, Torino, Italy, , , , , , IT
    S. Danese & G. Richiardi
  3. Ginecologia Oncologica, Azienda Ospedaliera Sant’Anna, Torino, Italy, , , , , , IT
    P. Zola & M. G. Baù
  4. Centro di Senologia, Azienda Ospedaliera Istituti Ospitalieri, Cremona, Italy, , , , , , IT
    A. Bottini
  5. Radioterapia, Ospedale di Biella, Italy, , , , , , IT
    G. Moro
  6. Oncologia Medica, Università di Sassari, Italy, , , , , , IT
    A. Farris
  7. Oncologia Medica, Ospedale di Alba, Italy, , , , , , IT
    G. Porcile

Authors

  1. L. Dogliotti
    You can also search for this author inPubMed Google Scholar
  2. S. Danese
    You can also search for this author inPubMed Google Scholar
  3. A. Berruti
    You can also search for this author inPubMed Google Scholar
  4. P. Zola
    You can also search for this author inPubMed Google Scholar
  5. T. Buniva
    You can also search for this author inPubMed Google Scholar
  6. A. Bottini
    You can also search for this author inPubMed Google Scholar
  7. G. Richiardi
    You can also search for this author inPubMed Google Scholar
  8. G. Moro
    You can also search for this author inPubMed Google Scholar
  9. A. Farris
    You can also search for this author inPubMed Google Scholar
  10. M. G. Baù
    You can also search for this author inPubMed Google Scholar
  11. G. Porcile
    You can also search for this author inPubMed Google Scholar

Additional information

Received: 1 January 1997 / Accepted: 22 July 1997

Rights and permissions

About this article

Cite this article

Dogliotti, L., Danese, S., Berruti, A. et al. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.Cancer Chemother Pharmacol 41, 333–338 (1998). https://doi.org/10.1007/s002800050747

Download citation